Strategies for urgent reversal of target-specific oral anticoagulants

Estella M. Davis, Erin M. Uhlmeyer, David P. Schmidt, Greg L. Schardt

Research output: Contribution to journalReview article

Abstract

The direct thrombin inhibitor dabigatran and factor Xa inhibitors rivaroxaban and apixaban are US Food and Drug Administration (FDA)-approved target-specific oral anticoagulants (TSOACs) that have emerged onto the market for use in some indications similar to those for warfarin; in addition, edoxaban is seeking FDA approval. Similar indications include reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation for all 3 agents, for the prevention of deep vein thrombosis that may lead to pulmonary embolism in patients undergoing hip or knee surgery for rivaroxaban and apixaban, and for the treatment and prevention of deep vein thrombosis and pulmonary embolism. As anticoagulants, they are all associated with a risk of bleeding, and, unfortunately, there are no approved antidotes for reversal of these agents. A number of small studies in human subjects and in human/animal models exposed to TSOACs have evaluated the use of activated charcoal, hemodialysis for dabigatran, or clotting factor concentrates for their ability to neutralize the anticoagulant effects or reduce drug concentrations of TSOACs. Clotting factor concentrates that have been used include prothrombin complex concentrates and recombinant factor VII. This review examines studies and case reports evaluating these strategies for expedited or emergent reversal of TSOACs.

Original languageEnglish
Pages (from-to)108-125
Number of pages18
JournalHospital practice (1995)
Volume42
Issue number5
DOIs
StatePublished - Dec 1 2014

Fingerprint

Anticoagulants
Blood Coagulation Factors
United States Food and Drug Administration
Pulmonary Embolism
Venous Thrombosis
Drug Approval
Antidotes
Factor VII
Antithrombins
Charcoal
Warfarin
Embolism
Atrial Fibrillation
Renal Dialysis
Hip
Knee
Animal Models
Stroke
Hemorrhage
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Strategies for urgent reversal of target-specific oral anticoagulants. / Davis, Estella M.; Uhlmeyer, Erin M.; Schmidt, David P.; Schardt, Greg L.

In: Hospital practice (1995), Vol. 42, No. 5, 01.12.2014, p. 108-125.

Research output: Contribution to journalReview article

Davis, Estella M. ; Uhlmeyer, Erin M. ; Schmidt, David P. ; Schardt, Greg L. / Strategies for urgent reversal of target-specific oral anticoagulants. In: Hospital practice (1995). 2014 ; Vol. 42, No. 5. pp. 108-125.
@article{e0aca3de968646c9bd36b204d4346c0d,
title = "Strategies for urgent reversal of target-specific oral anticoagulants",
abstract = "The direct thrombin inhibitor dabigatran and factor Xa inhibitors rivaroxaban and apixaban are US Food and Drug Administration (FDA)-approved target-specific oral anticoagulants (TSOACs) that have emerged onto the market for use in some indications similar to those for warfarin; in addition, edoxaban is seeking FDA approval. Similar indications include reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation for all 3 agents, for the prevention of deep vein thrombosis that may lead to pulmonary embolism in patients undergoing hip or knee surgery for rivaroxaban and apixaban, and for the treatment and prevention of deep vein thrombosis and pulmonary embolism. As anticoagulants, they are all associated with a risk of bleeding, and, unfortunately, there are no approved antidotes for reversal of these agents. A number of small studies in human subjects and in human/animal models exposed to TSOACs have evaluated the use of activated charcoal, hemodialysis for dabigatran, or clotting factor concentrates for their ability to neutralize the anticoagulant effects or reduce drug concentrations of TSOACs. Clotting factor concentrates that have been used include prothrombin complex concentrates and recombinant factor VII. This review examines studies and case reports evaluating these strategies for expedited or emergent reversal of TSOACs.",
author = "Davis, {Estella M.} and Uhlmeyer, {Erin M.} and Schmidt, {David P.} and Schardt, {Greg L.}",
year = "2014",
month = "12",
day = "1",
doi = "10.3810/hp.2014.12.1164",
language = "English",
volume = "42",
pages = "108--125",
journal = "Hospital practice (1995)",
issn = "2154-8331",
publisher = "Taylor and Francis Ltd.",
number = "5",

}

TY - JOUR

T1 - Strategies for urgent reversal of target-specific oral anticoagulants

AU - Davis, Estella M.

AU - Uhlmeyer, Erin M.

AU - Schmidt, David P.

AU - Schardt, Greg L.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - The direct thrombin inhibitor dabigatran and factor Xa inhibitors rivaroxaban and apixaban are US Food and Drug Administration (FDA)-approved target-specific oral anticoagulants (TSOACs) that have emerged onto the market for use in some indications similar to those for warfarin; in addition, edoxaban is seeking FDA approval. Similar indications include reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation for all 3 agents, for the prevention of deep vein thrombosis that may lead to pulmonary embolism in patients undergoing hip or knee surgery for rivaroxaban and apixaban, and for the treatment and prevention of deep vein thrombosis and pulmonary embolism. As anticoagulants, they are all associated with a risk of bleeding, and, unfortunately, there are no approved antidotes for reversal of these agents. A number of small studies in human subjects and in human/animal models exposed to TSOACs have evaluated the use of activated charcoal, hemodialysis for dabigatran, or clotting factor concentrates for their ability to neutralize the anticoagulant effects or reduce drug concentrations of TSOACs. Clotting factor concentrates that have been used include prothrombin complex concentrates and recombinant factor VII. This review examines studies and case reports evaluating these strategies for expedited or emergent reversal of TSOACs.

AB - The direct thrombin inhibitor dabigatran and factor Xa inhibitors rivaroxaban and apixaban are US Food and Drug Administration (FDA)-approved target-specific oral anticoagulants (TSOACs) that have emerged onto the market for use in some indications similar to those for warfarin; in addition, edoxaban is seeking FDA approval. Similar indications include reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation for all 3 agents, for the prevention of deep vein thrombosis that may lead to pulmonary embolism in patients undergoing hip or knee surgery for rivaroxaban and apixaban, and for the treatment and prevention of deep vein thrombosis and pulmonary embolism. As anticoagulants, they are all associated with a risk of bleeding, and, unfortunately, there are no approved antidotes for reversal of these agents. A number of small studies in human subjects and in human/animal models exposed to TSOACs have evaluated the use of activated charcoal, hemodialysis for dabigatran, or clotting factor concentrates for their ability to neutralize the anticoagulant effects or reduce drug concentrations of TSOACs. Clotting factor concentrates that have been used include prothrombin complex concentrates and recombinant factor VII. This review examines studies and case reports evaluating these strategies for expedited or emergent reversal of TSOACs.

UR - http://www.scopus.com/inward/record.url?scp=84925221752&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925221752&partnerID=8YFLogxK

U2 - 10.3810/hp.2014.12.1164

DO - 10.3810/hp.2014.12.1164

M3 - Review article

VL - 42

SP - 108

EP - 125

JO - Hospital practice (1995)

JF - Hospital practice (1995)

SN - 2154-8331

IS - 5

ER -